MetaCap

COMPASS Pathways Plc American Depository Shares (CMPS)

NASDAQ: CMPSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.05-0.60 (-6.94%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CMPS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.34
52-week range
4.88 – 15.87
Day range
7.82 – 8.43
Volume / Avg
6.09M / 3.09M
Beta
—

52-week range

$4.88$15.87

CMPS stock today

COMPASS Pathways Plc American Depository Shares (CMPS) closed at $8.05 on Nov 20, down 6.94% (-$0.60), versus the S&P 500's 3.70% decline. Shares are 49.3% below their 52-week high of $15.87, set on Sep 9, 2026 and 65.0% above the 52-week low of $4.88, in the middle of the past year's range. CMPS is up 16.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 55.7%.

COMPASS Pathways Plc American Depository Shares has posted a net loss over the last twelve months (EPS of -$2.34), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About COMPASS Pathways Plc American Depository Shares

Company profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Kabir Kumar Nath M.A., M.B.A.
Headquarters
London
Employees
156
IPO year
2020

Financial highlights

Full financials

COMPASS Pathways Plc American Depository Shares reported a net loss of $287.9 million, compared with a loss of $155.1 million a year earlier. Diluted earnings per share came in at -$3.08.

COMPASS Pathways Plc American Depository Shares annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-287.86M$-155.12M$-118.46M$-91.50M$-71.74M
EPS (diluted)$-3.08$-2.30$-2.32$-2.16$-1.79

Analyst forecast

Forecast

Consensus (16 analysts)

strong_buy

Avg. price target

$23.31+189.57%

  • Strong buy 3
  • Buy 12
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $65.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-0.31 vs $-0.39
Surprise
+20.51%

CMPS news

All CMPS news

COMPASS Pathways Plc American Depository Shares peers

Health Care sector
CMPS peer companies
CompanyPrice% ChgMarket capCompare
HROWHarrow Inc.30.41-5.35%$1.14Bvs CMPS
GPCRStructure Therapeutics Inc. ADR16.13-5.78%$1.15Bvs CMPS
AAPGAscentage Pharma Group International American Depository Shares11.97-3.78%$1.12Bvs CMPS
OPKOPKO Health Inc.1.57-2.48%$1.17Bvs CMPS
KARDKardigan Inc.11.54-7.83%$1.08Bvs CMPS
GHRSGH Research PLC17.53-5.55%$1.20Bvs CMPS
AMPHAmphastar Pharmaceuticals Inc.28.25+0.50%$1.20Bvs CMPS
MLYSMineralys Therapeutics Inc.13.66-3.53%$1.21Bvs CMPS

Indexes, lists and sector

COMPASS Pathways Plc American Depository Shares stock FAQ

What is COMPASS Pathways Plc American Depository Shares's stock price today?

CMPS last traded at $8.05 as of Nov 20, 4:00 PM EST, down 6.94% on the day. Prices are delayed at least 15 minutes.

Who is COMPASS Pathways Plc American Depository Shares's CEO?

Mr. Kabir Kumar Nath M.A., M.B.A. is the chief executive officer of COMPASS Pathways Plc American Depository Shares, which has about 156 employees.

What is the CMPS 52-week high?

The 52-week high for CMPS is $15.87 and the 52-week low is $4.88. The stock is currently 49.3% below its high.

Compare CMPS